HEPATOBILIARY CANCER

This adverse event was reported 60 times

These drugs are most commonly taken by patients reporting HEPATOBILIARY CANCER:

# Drug Count
0 INSULIN GLARGINE 7
1 METFORMIN 7
2 VALSARTAN 6
3 ASPIRIN 5
4 ASPIRIN 325 MG 5
5 ASPIRIN 81 MG 5
6 INSULIN ASPART 5
7 METFORMIN ER 500 MG 5
8 METFORMIN ER 750 MG 5
9 ADALIMUMAB 4
See all common drugs associated with HEPATOBILIARY CANCER

HEPATOBILIARY CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 BEZLOTOXUMAB 1 0.0029
1 CHLOROQUINE PHOSPHATE 1 0.0015
2 PEMIGATINIB 1 0.0012
3 PREDNISOLONE SODIUM PHOSPHATE 1 0.0004
4 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE 1 0.0004
5 AZILSARTAN KAMEDOXOMIL 1 0.0003
6 DIPYRIDAMOLE 1 0.0003
7 ACITRETIN 1 0.0002
8 DURVALUMAB 4 0.0002
9 CLINDAMYCIN PHOSPHATE 1 0.0002
See all drugs enriched for association with HEPATOBILIARY CANCER

HEPATOBILIARY CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Programmed Death Ligand-1 Blocker [EPC] 4 0.0002
1 Somatostatin Analog [EPC] 1 0.0001
2 Bile Acid [EPC] 2 0.0001
3 Purine Antimetabolite [EPC] 4 0.0000
4 GLP-1 Receptor Agonist [EPC] 11 0.0000
5 Calcineurin Inhibitor Immunosuppressant [EPC] 3 0.0000
6 Folate Analog [EPC] 1 0.0000
7 Vitamin A [EPC] 1 0.0000
8 Interleukin-12 Antagonist [EPC] 2 0.0000
9 Interleukin-23 Antagonist [EPC] 2 0.0000
See all drug classes enriched for association with HEPATOBILIARY CANCER